Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

FILE - This image provided by Eli Lilly shows the company's new Alzheimer's drug Kisunla. (Eli Lilly and Company via AP) 31,560 people played the daily Crossword recently. Can you solve it faster ...

Lilly said Friday that it hopes discussions about the drug continue with the agency ... that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.

(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...